Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA wants another clinical trial for Duchenne muscular dystrophy treatment; focus moves to Sarepta's candidate, which gets committee review next week.


Related Content

Once More Unto The Breach: PTC's Duchenne Drug Translarna Gets Advisory Cmte.
‘File Over Protest’ At US FDA: PTC To Pursue Rarely-Used Pathway For DMD Drug
Patient-Driven Drug Development Requires New Transparency Policies
Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
Sarepta Wins Exon 51 Composition Patent Rights Over BioMarin
Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows
Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago
Keeping Track: KemPharm Apadaz Delay; Cholera Vaccine Approved
Drisapersen Advisory Committee Is Rough Welcome To FDA For Patient Groups
Orphan Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts